Retatrutide (research phase) Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors
Without dairy products, gluten, soy, GMOs, caffeine, sugar, and cholesterol
Its synthetic forms, most notably disodium EDTA and calcium disodium EDTA, were discovered and reproduced in labs as early as 1935
Freezing damages the peptide structure irreversibly, reducing or eliminating its weight-loss effects
To ensure quality and safety, 503A pharmacies must comply with United States Pharmacopeia guidelines, specifically USP 795 for non-sterile compounding and USP 797 for sterile compounding
But if used improperly, other effortslike a chewing gum that claims to sculpt a sharper jawlinemay have potentially negative consequences beyond just bleeding their parents wallets dry